Thought Leadership

Latest Report


Evaluate Vantage Biopharma and Venture Capital: A Deep Dive

The sheer amount of private capital available to young drug developers the last few years is nothing new, however the Covid-19 pandemic has brought about an unprecedented influx of new money into biopharma. How permanent will these new funds prove; is biopharma's importance and attributes finally being realised by investors, governments and…

Report library


Evaluate Vantage COVID-19 Report

Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…


Evaluate Pharma Orphan Drug Report 2020

What will the orphan drug landscape look like in 2024? Big pharma's recent dominance of the orphan market has fuelled calls to reform the orphan drug act in the US.…


Evaluate Vantage 2020 Preview

The Evaluate Vantage 2020 Preview predicts a rocky year ahead, with areas of significant growth contrasting with investor uncertainty. The industry closed 2019 with a…